About 1,223,979 results (2,966 milliseconds)

US20160151436A1 - Treatment of Herpes, Pseudomonas, Staph ...

https://patents.google.com/patent/US20160151436A1/en
The name Staphylococcus comes from the Greek staphyle meaning a bunch of grapes and kokkos meaning berry, and that is what staph look like under the microscope, ...

EP1513956A2 - Assay to detect replication competent viruses ...

https://patents.google.com/patent/EP1513956A2/en
... HSV), baculoviral vectors, cytomegalovirus (CMV) vectors ... would be by definition and is still considered herein as selectively replicating.

CA2687301C - Synthetic herpes simplex viruses type-1 for treatment ...

https://patents.google.com/patent/CA2687301C/en
... 0.90) or inactivated OncSyn virus (p = 0.84). Tumors of mice injected ... herpes simplex virus that does not comprise gBsyn3. 2. The virus as in Claim ...

WO2017223248A1 - Method for delivering rna to neurons to treat ...

https://patents.google.com/patent/WO2017223248A1/en
Whether rAAV vectors would be delivered to the same sensory neurons that herpes simplex virus (HSV-1) infects when applied peripherally, at an epithelial ...

CA2721510A1 - Methods for treating herpes virus infections ...

https://patents.google.com/patent/CA2721510A1/en
Oct 22, 2009 ... Abreva has been shown to shorten mean time to healing by approximately a half-day. ... It does not cure herpes infections but decreases pain and ...

US10206996B2 - Herpes simplex virus nanoemulsion vaccine ...

https://patents.google.com/patent/US10206996B2/ja
An optimal vaccine against HSV would not only prevent against acute viral ... 0.90%, less than about 0.80%, less than about 0.70%, less than about 0.60 ...

WO2020055382A1 - Topical immunosensitizers to treat viral and ...

https://patents.google.com/patent/WO2020055382A1/en
... does not comprise applying the ... Several prior reports also found IFN-gamma to be important in controlling HSV infection and reducing HSV outbreaks.

US6369101B1 - Therapeutic method to treat herpes virus infection ...

https://patents.google.com/patent/US6369101B1/en
Specific values listed below for radicals, substituents, and ranges, are for illustration only; they do not exclude other defined values or other values within ...

US20120219602A1 - Methods for treating herpes virus infections ...

https://patents.google.com/patent/US20120219602A1/en
Abreva® has been shown to shorten mean time to healing by approximately a half-day. ... It does not cure herpes infections but decreases pain and itching, helps ...

US10206996B2 - Herpes simplex virus nanoemulsion vaccine ...

https://patents.google.com/patent/US10206996B2/en
... 0.90%, less than about 0.80%, less than about 0.70%, less than about 0.60 ... An optimal vaccine against HSV would not only prevent against acute viral ...

WO2019126472A1 - Use of pilra binding agents for treatment of a ...

https://patents.google.com/patent/WO2019126472A1/en
Interestingly, expression of PILRA on cells enhances HSV-1 entry, whereas expression of Paired Immunoglobulin-like Type 2 Receptor Beta (PILRB) does not (see, ...

US11147869B2 - Herpes simplex virus nanoemulsion vaccine ...

https://patents.google.com/patent/US11147869B2/en
However, this reference does not teach the ability to induce a protective immune response to HSV using the immunogens of the invention. Prior art directed to ...

AU2016209471A1 - Analytical ultracentrifugation for ...

https://patents.google.com/patent/AU2016209471A1/en
... 0.90. In some embodiments, the regularization is applied to a fitting ... In some embodiments, the HSV particle is an HSV-1 particle or an HSV-2 particle.

EP2280690A2 - Methods for treating herpes virus infections ...

https://patents.google.com/patent/EP2280690A2/en
Abreva® has been shown to shorten mean time to healing by approximately a half-day. ... It does not cure herpes infections but decreases pain and itching, helps ...

CN102083415A - Methods for treating herpes virus infections ...

https://patents.google.com/patent/CN102083415A/en
Cytomegalovirus does not cause symptom in children, and disease is gentle ... 0.90%, less than about 0.80%, less than about 0.70%, less than about 0.60 ...

deeplabcut_data_example.ipynb - Colab

https://colab.research.google.com/github/jgraving/deepposekit/blob/master/examples/deeplabcut_data_example.ipynb
This notebook shows you how to use the openfield example dataset from Mathis et al. (2018) to train a deep learning model using data augmentation and callbacks ...

CA2858347C - V1v2 immunogens - Google Patents

https://patents.google.com/patent/CA2858347C/en
Synagis (anti- respiratory syncytial virus mAb) and HIV-1 A32 mAbs were used as negative arid positive controls, respectively. Mean fluorescence intensity (MEI) ...

step3_train_model.ipynb - Colab

https://colab.research.google.com/github/jgraving/deepposekit/blob/master/examples/step3_train_model.ipynb
... 0.90, 100%: 1.14) 84/84 [==============================] - 72s ... Epoch 00088: val_loss did not improve from 42.42029 evaluation_metrics: euclidean - mean ...

EP3495385A1 - Viral inactivation using improved solvent-detergent ...

https://patents.google.com/patent/EP3495385A1/en
... HSV thymidine kinase, early and late simian virus 40 (SV40), LTRs from ... This mean specific activity is higher than 5,809 Ul/mg, the mean ...

US6984720B1 - Human CTLA-4 antibodies - Google Patents

https://patents.google.com/patent/US6984720B1/en
A “pharmaceutically acceptable salt” refers to a salt that retains the desired biological activity of the parent compound and does ... HSV-1, HAV-6, HSV-II ...